The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...

Researchers conducted a prospective study to examine the association between serum 25(OH)D levels at the age of 3 years and the risk for the onset of eosinophilic asthma by the age of 6 years ...

This is especially true for a subtype known as eosinophilic asthma -- asthma that's related to the recruitment and overactivation of white blood cells in the lungs called eosinophils. However ...

The EMA and counterparts in China and Japan are assessing the anti-IL-5 antibody as an add-on maintenance treatment for asthma patients aged 12 and over who have eosinophilic asthma, a form ...

Adolescents and adults with eosinophilic esophagitis improved with dupilumab regardless of whether they were practicing food ...

Treatment for eosinophilic esophagitis often involves collaboration between specialists, but patients face challenges in ...

They’ll determine the best dosage to fit your needs. Condition Ages Recommended dose Frequency severe eosinophilic asthma children ages 6 to 11 years 40 mg once every 4 weeks severe eosinophilic ...

In this randomized, placebo-controlled replicate trial, depemokimab decreased the annual rate of exacerbations among patients ...

The Oklahoma Allergy and Asthma clinic is pushing back against proposed changes in coverage for asthma medications covered by ...

A Prescription Drug User Fee Act target date of December 16, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License ...